ARAY
BEARISH
$0.37
Live
Accuray Incorporated · NASDAQ
Target $2.52
(+581.7%)
$0.33
52W Range
$2.1
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Mar 14, 2026
Market cap
$44.0M
P/E
N/A
ROE
-70.3%
Profit margin
-8.2%
Debt/Equity
2.9
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
ARAY's Piotroski F-Score of 4/9 indicates weak financial health, with a critical debt-to-equity ratio of 2.90 and negative ROE of -70.32%, signaling significant operational and solvency concerns. Despite a 16.8% year-over-year revenue growth, the company remains unprofitable with a negative profit margin of -8.15% and erratic earnings performance, including a -650% YoY EPS decline. The stock trades at a deeply discounted price-to-sales of 0.10 and price-to-book of 0.82, but this reflects severe market skepticism due to persistent losses and high financial risk. Analysts have a target price of $2.52, implying a potential 580% upside, yet this is based on minimal coverage and no consensus, underscoring speculative risk. The lack of insider activity and technical bearishness further reinforce a high-risk profile.
Key Strengths
16.8% year-over-year revenue growth indicates top-line expansion in a competitive healthcare sector
Price-to-sales ratio of 0.10 suggests deep undervaluation relative to sales
Positive operating margin of 3.73% shows some operational efficiency despite net losses
Gross margin of 27.85% reflects decent product-level profitability
Insider sentiment at 60/100 indicates moderate confidence from insiders
Key Risks
Piotroski F-Score of 4/9 signals weak financial health and deteriorating fundamentals
Negative ROE (-70.32%) and ROA (-1.18%) indicate severe capital inefficiency and losses
Debt-to-equity ratio of 2.90 is dangerously high, especially for a loss-making firm
Earnings volatility with average surprise of -79.85% over last 4 quarters and multiple negative surprises exceeding -150%
No dividend, no free cash flow, and no analyst consensus reduce investment appeal
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
29
Weak
60
40
25
20
0
AI Verdict
High Risk
Key drivers: Weak Piotroski F-Score, Negative profitability and ROE, High leverage and financial distress risk, Speculative valuation with no earnings support, Lack of analyst consensus and technical momentum
Confidence
85%
Value
60/100
Ref P/E, PEG, Graham Number
Positives
- Price-to-sales of 0.10 is extremely low
- Price-to-book of 0.82 suggests trading below book value
Watchpoints
- No Graham Number or intrinsic value due to negative earnings
- Valuation is not supported by profitability or cash flow
- Deep discount reflects market fear, not true undervaluation
Future
40/100
Ref Growth rates
Positives
- 16.8% YoY revenue growth indicates growth potential
- Recent Q/Q EPS growth of +21.4% shows possible improvement
Watchpoints
- Forward P/E of -12.35 indicates continued losses
- Earnings growth YoY is -650%, signaling deterioration
- No clear path to sustained profitability
Past
25/100
Ref Historical trends
Positives
- Some quarters beat estimates (e.g., +150% surprise in 2023-02-01)
- Historical EPS volatility shows occasional upside surprises
Watchpoints
- Average earnings surprise of -79.85% over last 4 quarters
- Multiple quarters with surprise > -150% (e.g., -259.9% in 2024-05-01)
- Persistent net losses and declining profitability
Health
20/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current ratio of 1.47 indicates short-term liquidity
- Operating margin of 3.73% shows some operational control
Watchpoints
- Piotroski F-Score of 4/9 is below threshold for financial stability
- Debt-to-equity of 2.90 is high and unsustainable for a loss-making firm
- Negative ROE and ROA indicate poor capital utilization
- No Altman Z-Score available, but debt levels suggest distress risk
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio
- Dividend strength is 0/100, indicating no income component
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$0.37
Analyst Target
$2.52
Upside/Downside
+581.7%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ARAY and closest competitors.
Updated 2026-03-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ARAY
Accuray Incorporated
Primary
|
-93.2% | -87.0% | -78.7% | -76.4% | -27.4% | -24.4% |
|
ZYBT
Zhengye Biotechnology Holding Limited
Peer
|
-81.1% | -81.1% | -88.2% | -63.5% | +5.8% | -10.7% |
|
RLYB
Rallybio Corporation
Peer
|
-92.7% | -76.3% | +311.0% | +92.1% | -12.2% | -2.6% |
|
RNXT
RenovoRx, Inc.
Peer
|
-86.2% | -68.2% | -2.0% | -10.7% | -2.9% | +1.5% |
|
APLM
Apollomics, Inc.
Peer
|
-98.0% | -98.1% | +148.8% | +191.4% | -0.5% | -0.8% |
ARA
Accuray Incorporated
Primary
5Y
-93.2%
3Y
-87.0%
1Y
-78.7%
6M
-76.4%
1M
-27.4%
1W
-24.4%
ZYB
Zhengye Biotechnology Holding Limited
Peer
5Y
-81.1%
3Y
-81.1%
1Y
-88.2%
6M
-63.5%
1M
+5.8%
1W
-10.7%
RLY
Rallybio Corporation
Peer
5Y
-92.7%
3Y
-76.3%
1Y
+311.0%
6M
+92.1%
1M
-12.2%
1W
-2.6%
RNX
RenovoRx, Inc.
Peer
5Y
-86.2%
3Y
-68.2%
1Y
-2.0%
6M
-10.7%
1M
-2.9%
1W
+1.5%
APL
Apollomics, Inc.
Peer
5Y
-98.0%
3Y
-98.1%
1Y
+148.8%
6M
+191.4%
1M
-0.5%
1W
-0.8%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-12.35
PEG Ratio
N/A
P/B Ratio
0.82
P/S Ratio
0.1
EV/Revenue
0.29
EV/EBITDA
-74.73
Market Cap
$44.0M
Profitability
Profit margins and return metrics
Profit Margin
-8.15%
Operating Margin
3.73%
Gross Margin
27.85%
ROE
-70.32%
ROA
-1.18%
Growth
Revenue and earnings growth rates
Revenue Growth
+16.8%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
2.9
High debt
Current Ratio
1.47
Good
Quick Ratio
0.6
Poor
Cash/Share
$0.98
Quarterly Earnings History
EPS performance vs analyst estimates
2026-04-29
$N/A
2026-02-04
$-0.11
+2.2% surprise
2025-11-05
$-0.14
-178.4% surprise
2025-08-13
$0.01
-63.3% surprise
Healthcare Sector Comparison
Comparing ARAY against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
Return on Equity (ROE)
-70.32%
This Stock
vs
-88.14%
Sector Avg
-20.2%
(Below Avg)
Profit Margin
-8.15%
This Stock
vs
-16.28%
Sector Avg
-49.9%
(Weaker)
Debt to Equity
2.9
This Stock
vs
2.66
Sector Avg
+8.8%
(Higher)
Revenue Growth
16.8%
This Stock
vs
124.04%
Sector Avg
-86.5%
(Slower)
Current Ratio
1.47
This Stock
vs
4.47
Sector Avg
-67.2%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ARAY
Accuray Incorporated
|
BEARISH | $44.0M | - | -70.3% | -8.2% | $0.37 | |
|
ZYBT
Zhengye Biotechnology...
|
BEARISH | $43.6M | - | -6.4% | -12.6% | $0.92 | Compare |
|
RLYB
Rallybio Corporation
|
BEARISH | $43.48M | - | -15.0% | -% | $8.22 | Compare |
|
RNXT
RenovoRx, Inc.
|
BEARISH | $45.05M | - | -225.6% | -% | $1.0 | Compare |
|
APLM
Apollomics, Inc.
|
BEARISH | $42.65M | - | -380.1% | -% | $19.9 | Compare |
ARAY
Accuray Incorporated
BEARISH
Mkt Cap
$44M
P/E
-
ROE
-70.3%
Price
$0.37
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-27 | PERALTA LEONEL | Chief Operating Officer | Stock Award | 83,723 | - |
| 2026-02-20 | MAYER STEVEN F | Director | Purchase | 54,875 | $30,878 |
| 2026-02-19 | MAYER STEVEN F | Director | Purchase | 195,125 | $103,797 |
| 2025-12-31 | SCOTT BYRON C | Director | Stock Award | 9,433 | - |
| 2025-11-28 | CHALKE SANDEEP | Officer | Stock Award | 50,314 | - |
| 2025-11-28 | PERVAIZ ALI | Chief Financial Officer | Stock Award | 44,025 | - |
| 2025-11-28 | MAYER STEVEN F | Director | Stock Award | 895,391 | - |
| 2025-11-28 | GALBATO CHAN W | Director | Stock Award | 50,000 | - |
| 2025-11-21 | LE GRAND ANNE BRYCE | Director | Stock Award | 56,603 | - |
| 2025-11-21 | SCOTT BYRON C | Director | Stock Award | 56,603 | - |
| 2025-11-21 | NISHIMURA MIKA | Director | Stock Award | 56,603 | - |
| 2025-11-21 | WHITTERS JOSEPH E | Director | Stock Award | 56,603 | - |
| 2025-11-21 | MAYER STEVEN F | Director | Stock Award | 45,620 | - |
| 2025-11-21 | HINDMAN JAMES M | Director | Stock Award | 56,603 | - |
| 2025-11-21 | HUSS BEVERLY A | Director | Stock Award | 56,603 | - |
PERALTA LEONEL
Chief Operating Officer
2026-02-27
83,723 shares
MAYER STEVEN F
Director
2026-02-20
54,875 shares
·
$30,878
MAYER STEVEN F
Director
2026-02-19
195,125 shares
·
$103,797
SCOTT BYRON C
Director
2025-12-31
9,433 shares
CHALKE SANDEEP
Officer
2025-11-28
50,314 shares
PERVAIZ ALI
Chief Financial Officer
2025-11-28
44,025 shares
MAYER STEVEN F
Director
2025-11-28
895,391 shares
GALBATO CHAN W
Director
2025-11-28
50,000 shares
LE GRAND ANNE BRYCE
Director
2025-11-21
56,603 shares
SCOTT BYRON C
Director
2025-11-21
56,603 shares
NISHIMURA MIKA
Director
2025-11-21
56,603 shares
WHITTERS JOSEPH E
Director
2025-11-21
56,603 shares
MAYER STEVEN F
Director
2025-11-21
45,620 shares
HINDMAN JAMES M
Director
2025-11-21
56,603 shares
HUSS BEVERLY A
Director
2025-11-21
56,603 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
2 analysts
BTIG
2026-02-05
Buy
Buy
BTIG
2025-11-06
Buy
Buy
Past News Coverage
Recent headlines mentioning ARAY from our newsroom.
Newest → oldest
No matching news yet.